[Preliminary note on the antiautistic, antidelusional and hallucinolytic effect of teflutixol (author's transl)].
The first thioxanthene derivative without the double bind up to now considered mandatory for the antipsychotic effect, teflutixol, was administered in a phase II pilot efficacy trial to acute or subacute psychotic inpatients (mean age 36,1) during at least 5 weeks at a dosage of 3 to 20 mg p.d. once a day. The patients were abruptly switched from a haloperidol baseline therapy, which was administered on an average for 3 weeks at 15 mg p.d. Preliminary results are reported for the first 11 patients on a purely clinical basis. Despite the limitations of a small sample and of a qualitative analysis of data, it is hypothesized that teflutixol is a potent and original neuroleptic drug combining at 6 mg p.d. or less potent antidelusional, hallucinolytic and antiautistic effects. Latency and duration of action approximate 2 days. At 6 mg and above appear side-effects of the desinhibiting type (anxious and/or aggressive mood, withdrawal, flaring up of delusions, insomnia, agitation) and extrapyramidal side-effects of the akathisia type. No adrenolytic, anticholinergic or toxic effects were prominent. The patient followed up for the longest period (6 months on 3 mg p.d.) has not relapsed and has normal liver functions.
D000328:Adult; D001321:Autistic Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003702:Delusions / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006212:Hallucinations / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy; D013892:Thioxanthenes / Q000008:administration & dosage / Q000627:therapeutic use*
D013892:Thioxanthenes
Note préliminaire sur l'effet anti-autistique, antidélirant et antihallucinatoire du teflutixol.